Nuformix plc (LON:NFX – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as GBX 0.16 ($0.00) and last traded at GBX 0.16 ($0.00), with a volume of 198199 shares. The stock had previously closed at GBX 0.17 ($0.00).
Nuformix Stock Down 4.7 %
The firm has a market cap of £1.33 million, a price-to-earnings ratio of -1.63 and a beta of 0.28. The business’s 50-day moving average is GBX 0.19 and its 200-day moving average is GBX 0.25. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.51.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Nuformix
- What is a Bond Market Holiday? How to Invest and Trade
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Progress Software Stock Back in the Green After Beating Forecasts
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
